Staff Writer

Cabometyx combinations showed activity in patients with GU cancers, according to a preliminary clinical study.

A recent study examined the symptoms and impairments for patients with MPNs.

Lynparza imrpoved progresion-free survival (PFS) when compared to the placebo group in a phase 3 ovarian cancer trial.

A trial testing Zytiga's effectiveness in ovarian cancer was recently halted.

The addition of immunotherapy did not show an improved progression-free survival for some patients with head and neck cancer.

A recent trial presented an unexpected survival benefit for patients with high-risk soft tissue sarcoma who were on anthracycline-based neoadjuvant chemotherapy.

Findings from a recent trial show that frontline Opdivo did not improve progression-free survival over chemotherapy in certain patients with lung cancer.

Pelvic intensity-modulated radiation therapy (IMRT) showed a decrease in gastrointestinal toxicity in women with cervical and ovarian cancer, according to a recent study.

Thanks to an addition of three biological markers to conventional breast cancer risk models, women can now better determine if they are at high or low risk for developing the disease.

Five years from now multiple myeloma will have a therapeutic backbone consisting entirely of combinations of novel agents, a leading myeloma researcher predicts.

Questions persist regarding mechanisms of PD-L1 overexpression in lymphoid malignancies, patient selection, biomarkers to guide therapy and predict response, and identification of agents to use in combination with PD-1/PD-L1 inhibitors.

This reanalysis confirmed that there is no difference for a radiotherapy-first versus a chemotherapy-first strategy in this setting, but there is a major difference in long-term outcomes for molecular stratification independent of treatment.

Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies, according to a preliminary analysis of data from an ongoing study.

While it's clear that cancer immunotherapies can be very expensive, there is help available to patients when it comes to deciding whether to take such treatments.

An analysis of three interrelated biomarkers in high-risk low-grade glioma (LGG) has identified distinct risk groups by isocitrate dehydrogenase (IDH) mutation status and suggested appropriate treatment strategies.

Data from an ongoing trial showed that one fourth of patients with PD-1-positive advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor Keytruda.